lenti-APOE2.EGFP

lenti-APOE2.EGFP is an experimental gene therapy candidate designed to deliver the protective APOE2 variant of the apolipoprotein E gene. Developed by researchers at the University of Bristol, the therapy utilizes a third-generation lentiviral vector to transduce autologous CD34+ hematopoietic stem cells (HSCs) ex vivo. These modified HSCs, which also express an enhanced green fluorescent protein (EGFP) reporter for tracking, are intended to be transplanted back into the patient. The therapeutic rationale is that HSC-derived cells will engraft in the brain and express the ApoE2 protein, which is known to have neuroprotective effects and reduce the risk or progression of Alzheimer's disease. Preclinical studies in APOE knockout mouse models have demonstrated successful engraftment and functional gene delivery.